プレスリリース

Illumina Completes Acquisition of GenoLogics

SAN DIEGO--(BUSINESS WIRE)--Sep. 1, 2015-- Illumina, Inc. (NASDAQ: ILMN) today announced it has completed the acquisition of GenoLogics Life Science Software Inc., a developer of industry leading laboratory information management systems (LIMS) for life sciences organizations.

"We look forward to working with the talented team at GenoLogics and to further integrate their life science software as part of the overall Illumina informatics solution," said Francis deSouza, President of Illumina. “Adopted by more than 120 genomic labs worldwide, GenoLogics’s Clarity LIMS software strengthens our industry leading portfolio of genetic analysis solutions.”

The completion of the acquisition demonstrates Illumina’s commitment to drive the adoption of sequencing in new markets and improve the genomic workflow. GenoLogics’ Clarity LIMS™ software enables lab efficiencies and improved sample throughput with increased accuracy, fast turnaround, sample traceability, and preconfigured instrument integrations.

Source: Illumina, Inc.

Illumina, Inc.
Investors:
Rebecca Chambers, 858-255-5243
rchambers@illumina.com
or
Media:
Eric Endicott, 858-882-6822
pr@illumina.com

最近の記事

ヒトゲノムの暗黒領域に潜む手がかりの探索
ヒトゲノムの暗黒領域に潜む手がかりの探索
精密医療の実現に向けて医療の進歩を支えるイルミナ社員の取り組み
精密医療の実現に向けて医療の進歩を支えるイルミナ社員の取り組み
複雑な卵巣症例における悪性・良性腫瘍の鑑別を支えるマルチオミクス
複雑な卵巣症例における悪性・良性腫瘍の鑑別を支えるマルチオミクス